Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

CAMBRIDGE, Mass., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, Spero's President and Chief Executive Officer, will participate in a fireside chat at the Chardan 10^th Annual Healthcare Conference to be held in New York City, on October 20^th, 2026. Spero's leadership team will also be available for one-on-one meetings at the conference.

Presentation Details
Date / time:	October 20, 2026, 9:15 AM ET
Format:	Fireside chat
Location:	Holmes II, Lotte New York Palace
Webcast Link	Here

The webcast may also be accessed through Spero's website on the Events + Presentations page. A replay will be available for approximately 90 days following the conference. To request a meeting or for more details about the conference please contact your institutional representative at Chardan.

About Spero Therapeutics

Spero Therapeutics is a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases. The company's lead program, SP001, is a third-generation, Fc-silent anti-CD40L monoclonal antibody being advanced first in IgG4-related disease, with potential for development in additional immunological & inflammatory diseases. For more information, visit www.sperotx.com.

Investor Relations Contact:
Shai Biran, PhD
Spero Therapeutics
IR@Sperotherapeutics.com

Media Inquiries:
media@sperotherapeutics.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.